Valuation: Orexo AB

Market Cap 174M 17.57M 15.76M 14.57M 13.2M 24.66M 1.67B 24.95M 69.39M 875M 65.92M 64.53M 2.78B P/E 2024
-2.97x
P/E 2025 1.63x
Enterprise Value -247M -24.87M -22.32M -20.63M -18.69M -34.91M -2.37B -35.33M -98.25M -1.24B -93.33M -91.36M -3.94B EV / Sales 2024
1.62x
EV / Sales 2025 23.8x
Free-Float
78.37%
Yield 2024 *
-
Yield 2025 -
1 day-0.32%
1 week-9.27%
Current month-65.84%
1 month-65.08%
3 months-67.27%
6 months-75.16%
Current year-84.39%
1 week 4.7
Extreme 4.7
5.44
1 month 4.7
Extreme 4.7
14.8
Current year 4.7
Extreme 4.7
36
1 year 4.7
Extreme 4.7
36
3 years 4.7
Extreme 4.7
43.4
5 years 4.7
Extreme 4.7
43.4
10 years 4.7
Extreme 4.7
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/25 A Buy

Chief Executive Officer

6 0.0000%
9/4/25 A Free

Chief Executive Officer

1,393 0.0040%
9/3/25 A Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-9.27%-83.51%-71.34% 17.57M
+6.94%+5.80%+69.94%+144.39% 1,148B
+1.57%+2.77%+47.39%+87.06% 652B
+1.60%+1.74%+28.87%+104.48% 505B
+0.98%+2.47%+54.30%+66.51% 384B
+5.18%+0.14%+70.30%+43.60% 348B
+2.74%+2.96%+34.72%+56.80% 294B
+2.50%+0.52%+3.89%+27.70% 264B
+2.61%+3.52%+58.69%+75.92% 244B
+1.86%+3.24%+36.95%+108.67% 197B
Average +2.58%+0.06%+32.15%+64.38% 403.72B
Weighted average by Cap. +3.61%+1.50%+50.53%+94.15%

Financials

2024 2025
Net sales 590M 59.49M 53.37M 49.35M 44.69M 83.49M 5.67B 84.5M 235M 2.96B 223M 219M 9.41B 26M 2.62M 2.35M 2.17M 1.97M 3.68M 250M 3.72M 10.36M 131M 9.84M 9.63M 415M
Net income -203M -20.47M -18.36M -16.98M -15.38M -28.73M -1.95B -29.08M -80.86M -1.02B -76.81M -75.19M -3.24B 639M 64.46M 57.83M 53.47M 48.43M 90.47M 6.14B 91.57M 255M 3.21B 242M 237M 10.2B
Net Debt 353M 35.56M 31.91M 29.5M 26.72M 49.91M 3.39B 50.52M 140M 1.77B 133M 131M 5.63B -421M -42.44M -38.08M -35.2M -31.88M -59.56M -4.04B -60.28M -168M -2.12B -159M -156M -6.71B
Projected Income Statement - Annual - Orexo AB
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
55
Date Price Change Volume
29/10/26 SEK 4.700 -0.32% 337,274
28/10/26 SEK 4.715 -3.38% 74,801
27/10/26 SEK 4.880 -4.50% 70,294
26/10/26 SEK 5.110 -1.92% 41,780
23/10/26 SEK 5.210 +0.58% 130,396
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Orexo AB

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orexo AB